Clinical Guest Contributors

  1. Social Media Is Replete With Patient RWD, But How Can Researchers Best Use It? 7/1/2026

    Pistoia Alliance's Thierry Escudier and Aditya Tyagi discuss how social media listening is used in clinical research, how it supports established evidence-generation methods, and how it can become a credible, structured input for drug development.

  2. How Translational Biomarker Research Could Change The Trajectory Of Hidradenitis Suppurativa 6/30/2026

    Elisa Maggioli, Ph.D., explains that improving outcomes in HS may depend on moving beyond broad, symptom-based approaches toward more targeted, biologically informed strategies.

  3. Unicycive Therapeutics' Framework For Speedier Clinical Trials 6/29/2026

    Unicycive Therapeutics Vice President of R&D Guru Reddy, Ph.D., shares how his small team moved swiftly through a recent early phase trial.

  4. Helus Shares Experience Studying Adjunctive Psychedelic For Major Depressive Disorder 6/26/2026

    Helus Pharma CMO Amir Inamdar discusses the strategic rationale behind its Phase 3 trial for major depressive disorder, including its adjunctive-treatment approach, patient population selection, and endpoint strategy.

  5. Understanding And Preserving Data Flow Integrity In AI-Assisted Clinical Trials 6/26/2026

    Learn from ex-FDA and ELIQUENT consultant Dawn Wydner, Ph.D.., how treating data integrity as an end-to-end clinical information flow issue, rather than a database-only concern, is essential to managing AI-related risk.

  6. RWE Increasingly Supports Rare Disease Research As RCTs Alone Fall Short 6/25/2026

    Chiesi's Rachele Berria, MD, Ph.D., discusses how RWE is reshaping rare disease drug development strategies, from leveraging registries and patient-reported outcomes to navigating evolving regulatory expectations.

  7. AI Can Help Design Better Trials, But It Still Can't Tell You Whether Patients Will Join Them 6/25/2026

    AI is changing the way clinical trial trials are discussed, planned, and designed. But even with an improved protocol, are AI-enhanced trials driving better enrollment?

  8. Will AI And Agile Project Management Help Advance RBM? 6/24/2026

    Will AI-based tools embedded into risk based-monitoring prompt an Agile project management moment for clinical research? Sidharth Ananthanarayan explains why AI-based tools are not the answer but part of it.

  9. The Next Chapter Of Obesity And Type 2 Diabetes Care: ADA 2026 Signals A More Personalized Future 6/23/2026

    The American Diabetes Association 2026 conference showed where we are and where we're going with GLP-1 therapies.

  10. Why Building Long-Term Value And Making Clinical Progress Are Inextricable 6/23/2026

    Dicot Pharma CEO Elin Trampe discusses how clinical milestones, financing strategy, shareholder value, and partnering considerations must be tightly integrated in early development through late-stage planning.